The risk of treatment versus the risk of HIV replication

Lancet

Volumn 367, Issue 9527, 2006, Pages 1955-1956

  Deeks, Steven G ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LIPID; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; ATHEROSCLEROSIS; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; DRUG POTENCY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; MALAISE; MOOD CHANGE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; VIRUS REPLICATION;

EID: 33744969817     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68857-0     Document Type: Note

References (8)

1. Gulick R., Mellors J., Havlir D., et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337 (1997) 734-739
2. Levy A., James D., Johnston K., et al. The direct costs of HIV/AIDS care. Lancet Infect Dis 6 (2006) 171-177
3. Danel C., Moh R., Minga A., and for the Trivacan ANRS 1269 trial group. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 367 (2006) 1981-1986
4. El-Sadr W, Neaton J, for the SMART Study Investigators. Episodic CD4 guided use of antiretroviral therapy is inferior to continuous therapy: results of the SMART study. 13th Conference on Retroviruses and Opportunistic Infections. Denver, Colarado, USA; Feb 5-8, 2006: 106LB (abst).
5. Maggiolo F., Ripamonti D., Gregis G., Quinzan G., Callegaro A., and Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 18 (2004) 439-446
6. Cardiello P., Hassink E., Ananworanich J., et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 40 (2005) 594-600
7. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. Denver, Colarado, USA; Feb 5-8, 2006: 102 (abst).
8. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents (May 4, 2006). http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed June 7, 2006)